Free Trial
→ SpaceX will crumble without these 5 companies (From InvestPub) (Ad)tc pixel Free AFIB Stock Alerts

Acutus Medical (AFIB) Competitors

Acutus Medical logo
Compare

AFIB vs. TTOO, UTRS, MOTS, DRTSW, and ANZUW

Should you buy Acutus Medical stock or one of its competitors? MarketBeat compares Acutus Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acutus Medical include T2 Biosystems (TTOO), Minerva Surgical (UTRS), Motus GI (MOTS), Alpha Tau Medical (DRTSW), and Anzu Special Acquisition Corp I (ANZUW). These companies are all part of the "medical equipment" industry.

How does Acutus Medical compare to T2 Biosystems?

Acutus Medical (NASDAQ:AFIB) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

In the previous week, T2 Biosystems had 1 more articles in the media than Acutus Medical. MarketBeat recorded 1 mentions for T2 Biosystems and 0 mentions for Acutus Medical. Acutus Medical's average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company Overall Sentiment
Acutus Medical Neutral
T2 Biosystems Neutral

56.9% of Acutus Medical shares are held by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are held by institutional investors. 5.2% of Acutus Medical shares are held by company insiders. Comparatively, 0.0% of T2 Biosystems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Acutus Medical has a beta of 5.68, meaning that its stock price is 468% more volatile than the broader market. Comparatively, T2 Biosystems has a beta of 7.8, meaning that its stock price is 680% more volatile than the broader market.

Acutus Medical has a net margin of -272.74% compared to T2 Biosystems' net margin of -563.16%. T2 Biosystems' return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Acutus Medical-272.74% -311.64% -11.57%
T2 Biosystems -563.16%N/A -174.06%

T2 Biosystems has higher revenue and earnings than Acutus Medical. T2 Biosystems is trading at a lower price-to-earnings ratio than Acutus Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

Summary

T2 Biosystems beats Acutus Medical on 6 of the 11 factors compared between the two stocks.

How does Acutus Medical compare to Minerva Surgical?

Acutus Medical (NASDAQ:AFIB) and Minerva Surgical (NASDAQ:UTRS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

56.9% of Acutus Medical shares are owned by institutional investors. 5.2% of Acutus Medical shares are owned by insiders. Comparatively, 8.5% of Minerva Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Minerva Surgical has a net margin of 0.00% compared to Acutus Medical's net margin of -272.74%. Minerva Surgical's return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Acutus Medical-272.74% -311.64% -11.57%
Minerva Surgical N/A N/A N/A

Minerva Surgical has higher revenue and earnings than Acutus Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A
Minerva Surgical$51.69M0.00-$34.11M-$4.21N/A

In the previous week, Acutus Medical's average media sentiment score of 0.00 equaled Minerva Surgical'saverage media sentiment score.

Company Overall Sentiment
Acutus Medical Neutral
Minerva Surgical Neutral

Acutus Medical has a beta of 5.68, suggesting that its stock price is 468% more volatile than the broader market. Comparatively, Minerva Surgical has a beta of 2.92, suggesting that its stock price is 192% more volatile than the broader market.

Summary

Minerva Surgical beats Acutus Medical on 7 of the 10 factors compared between the two stocks.

How does Acutus Medical compare to Motus GI?

Acutus Medical (NASDAQ:AFIB) and Motus GI (NASDAQ:MOTS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

Motus GI has a net margin of 0.00% compared to Acutus Medical's net margin of -272.74%. Motus GI's return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Acutus Medical-272.74% -311.64% -11.57%
Motus GI N/A N/A N/A

Motus GI has lower revenue, but higher earnings than Acutus Medical. Motus GI is trading at a lower price-to-earnings ratio than Acutus Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A
Motus GI$319K0.00-$12.87M-$14.69N/A

56.9% of Acutus Medical shares are owned by institutional investors. Comparatively, 20.1% of Motus GI shares are owned by institutional investors. 5.2% of Acutus Medical shares are owned by company insiders. Comparatively, 0.3% of Motus GI shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Acutus Medical's average media sentiment score of 0.00 equaled Motus GI'saverage media sentiment score.

Company Overall Sentiment
Acutus Medical Neutral
Motus GI Neutral

Acutus Medical has a beta of 5.68, meaning that its stock price is 468% more volatile than the broader market. Comparatively, Motus GI has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market.

Summary

Acutus Medical and Motus GI tied by winning 5 of the 10 factors compared between the two stocks.

How does Acutus Medical compare to Alpha Tau Medical?

Alpha Tau Medical (NASDAQ:DRTSW) and Acutus Medical (NASDAQ:AFIB) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Alpha Tau Medical has a net margin of 0.00% compared to Acutus Medical's net margin of -272.74%. Alpha Tau Medical's return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Alpha Tau MedicalN/A N/A N/A
Acutus Medical -272.74%-311.64%-11.57%

56.9% of Acutus Medical shares are held by institutional investors. 5.2% of Acutus Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Alpha Tau Medical had 1 more articles in the media than Acutus Medical. MarketBeat recorded 1 mentions for Alpha Tau Medical and 0 mentions for Acutus Medical. Alpha Tau Medical's average media sentiment score of 1.89 beat Acutus Medical's score of 0.00 indicating that Alpha Tau Medical is being referred to more favorably in the media.

Company Overall Sentiment
Alpha Tau Medical Very Positive
Acutus Medical Neutral

Alpha Tau Medical has higher earnings, but lower revenue than Acutus Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alpha Tau MedicalN/AN/AN/AN/AN/A
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A

Summary

Alpha Tau Medical beats Acutus Medical on 5 of the 8 factors compared between the two stocks.

How does Acutus Medical compare to Anzu Special Acquisition Corp I?

Acutus Medical (NASDAQ:AFIB) and Anzu Special Acquisition Corp I (NASDAQ:ANZUW) are both medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Anzu Special Acquisition Corp I has a net margin of 0.00% compared to Acutus Medical's net margin of -272.74%. Anzu Special Acquisition Corp I's return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Acutus Medical-272.74% -311.64% -11.57%
Anzu Special Acquisition Corp I N/A N/A N/A

56.9% of Acutus Medical shares are held by institutional investors. 5.2% of Acutus Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Anzu Special Acquisition Corp I has lower revenue, but higher earnings than Acutus Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A
Anzu Special Acquisition Corp IN/AN/AN/AN/AN/A

In the previous week, Acutus Medical's average media sentiment score of 0.00 equaled Anzu Special Acquisition Corp I'saverage media sentiment score.

Company Overall Sentiment
Acutus Medical Neutral
Anzu Special Acquisition Corp I Neutral

Summary

Acutus Medical and Anzu Special Acquisition Corp I tied by winning 3 of the 6 factors compared between the two stocks.

Get Acutus Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for AFIB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AFIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AFIB vs. The Competition

Export
MetricAcutus MedicalSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$3K$39.45M$6.52B$12.05B
Dividend YieldN/A1.08%2.67%5.66%
P/E Ratio0.0017.8224.0024.42
Price / SalesN/A27.38514.65112.54
Price / CashN/A18.8627.4837.92
Price / BookN/A12.2810.696.82
Net Income-$81.66M-$16.77M$3.57B$337.56M

Acutus Medical Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AFIB
Acutus Medical
N/AN/AN/AN/A$3K$7.16MN/A340
TTOO
T2 Biosystems
N/A$0.00
-80.0%		N/A-99.7%$8K$7.68MN/A180
UTRS
Minerva Surgical
N/AN/AN/AN/A$1K$51.69MN/A160
MOTS
Motus GI
N/AN/AN/AN/A$1K$319KN/A30
DRTSW
Alpha Tau Medical
N/A$1.83
+1.4%		N/A+773.3%$0.00N/AN/A80

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AFIB) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel